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Actinomyces in chronic granulomatous disease: an emerging and
unanticipated pathogen
Abstract
BACKGROUND: Chronic granulomatous disease (CGD) is a rare inherited disease of the phagocyte
NADPH oxidase system that causes defective production of toxic oxygen metabolites, impaired
bacterial and fungal killing, and recurrent life-threatening infections, mostly by catalase-producing
organisms. We report for the first time, to our knowledge, chronic infections with Actinomyces species
in 10 patients with CGD. Actinomycosis is a chronic granulomatous condition that commonly manifests
as cervicofacial, pulmonary, or abdominal disease, caused by slowly progressive infection with oral and
gastrointestinal commensal Actinomyces species. Treatment of actinomycosis is usually simple in
immunocompetent individuals, requiring long-term, high-dose intravenous penicillin, but is more
complicated in those with CGD because of delayed diagnosis and an increased risk of chronic invasive
or debilitating disease. METHODS: Actinomyces was identified by culture, staining, 16S ribosomal
DNA polymerase chain reaction, and/or a complement fixation test in 10 patients with CGD.
RESULTS: All 10 patients presented with a history of fever and elevated inflammatory signs without
evident focus. Diagnosis was delayed and clinical course severe and protracted despite high-dose
intravenous antibiotic therapy and/or surgery. These results suggest an unrecognized and unanticipated
susceptibility to weakly pathogenic Actinomyces species in patients with CGD because these are
catalase-negative organisms previously thought to be nonpathogenic in CGD. CONCLUSIONS:
Actinomycosis should be vigorously sought and promptly treated in patients with CGD presenting with
uncommon and prolonged clinical signs of infection. Actinomycosis is a catalase-negative infection
important to consider in CGD.
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Background. Chronic granulomatous disease (CGD) is a rare inherited disease of the phagocyte NADPH
oxidase system that causes defective production of toxic oxygen metabolites, impaired bacterial and fungal killing,
and recurrent life-threatening infections, mostly by catalase-producing organisms. We report for the first time, to
our knowledge, chronic infections with Actinomyces species in 10 patients with CGD. Actinomycosis is a chronic
granulomatous condition that commonly manifests as cervicofacial, pulmonary, or abdominal disease, caused by
slowly progressive infection with oral and gastrointestinal commensal Actinomyces species. Treatment of actino-
mycosis is usually simple in immunocompetent individuals, requiring long-term, high-dose intravenous penicillin,
but is more complicated in those with CGD because of delayed diagnosis and an increased risk of chronic invasive
or debilitating disease.
Methods. Actinomyces was identified by culture, staining, 16S ribosomal DNA polymerase chain reaction, and/
or a complement fixation test in 10 patients with CGD.
Results. All 10 patients presented with a history of fever and elevated inflammatory signs without evident
focus. Diagnosis was delayed and clinical course severe and protracted despite high-dose intravenous antibiotic
therapy and/or surgery. These results suggest an unrecognized and unanticipated susceptibility to weakly pathogenic
Actinomyces species in patients with CGD because these are catalase-negative organisms previously thought to be
nonpathogenic in CGD.
Conclusions. Actinomycosis should be vigorously sought and promptly treated in patients with CGD presenting
with uncommon and prolonged clinical signs of infection. Actinomycosis is a catalase-negative infection important
to consider in CGD.
Patients with chronic granulomatous disease (CGD)
develop recurrent life-threatening infections and tissue
granulomata [1, 2]. Bacteria and fungi that commonly
cause infection in CGD include Staphylococcus aure-
us, Serratia marcescens, Burkholderia cepacia complex,
Nocardia species, and Aspergillus species. Rare infec-
tions with organisms encountered almost exclusively in
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CGD, such as Paecilomyces species, Trichosporon inkin,
and Granulibacter bethesdensis [3], suggest that patients
with CGD have a unique susceptibility pattern that has
been thought previously to depend on microbial cat-
alase for virulence [1].
The genus Actinomyces consists of a heterogeneous
group of gram-positive, non–spore-forming, catalase-
negative pleomorphic rods [4] that form a significant
component of the commensal microflora of the oral,
gastrointestinal, and female genital tracts and that are
generally of low pathogenicity [5]. Actinomyces species
may invade via damaged mucosa, leading to bacteremia
and systemic infections [4] in both healthy individu-
als [6, 7] and immunocompromised patients [8–10].
Diagnosis of Actinomyces infection is often delayed be-
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cause of nonspecific and prolonged symptoms, resulting in de-
velopment of chronic debilitating disease.
Actinomycosis has not been reported previously in CGD,
except for 1 patient with pulmonary Actinomyces israelii men-
tioned in passing [11]. However, in this report we identify 10
severe chronic recurrent infections with Actinomyces species
from 3 immunodeficiency centers (National Institutes of Health
in Bethesda, Maryland; Paris, France; and Zurich, Switzerland),
representing each of the major localizations of human acti-
nomycosis, clearly demonstrating that actinomycosis is a sig-
nificant and previously unrecognized problem in CGD.
CASE REPORTS
Patient consent. Written informed consent was obtained
from all patients and/or parents.
Patient 1. Patient 1 was a 23-year-old Slovenian man with
X-linked CGD. He had a history of recurrent, cervical, fistu-
lizing lymphadenitis (only Corynebacterium aquaticum isolated
from culture samples) at the age of 19 years and a painless
submandibular abscess at the age of 22 years. He developed a
painless, tender swelling fixed to adjacent tissues. The lesion
was drained and culture yielded Actinomyces naeslundii. Treat-
ment with intravenous ceftriaxone did not lead to complete
resolution, despite surgical excision. The patient underwent
HLA-genoidentical bone marrow transplantation (BMT) at the
age of 23 years in Switzerland. Positron emission tomography–
computed tomography (CT) before BMT showed active in-
flammation in several lymph nodes of the right cervical region,
still present 1 month after BMT with full engraftment. Clini-
cally, the lesion resolved completely after 1 month of treatment
with intravenous meropenem, when therapy was changed to
oral penicillin for 3 months.
Patient 2. Patient 2 was a 6.5-year-old French boy with X-
linked CGD. He had a history of Serratia marcescens septicemia
at the age of 2 years, with hepatic, splenic, and lung abscesses,
pulmonary aspergillosis at the age of 3 years, and undiagnosed
severe bilateral pneumonitis despite lung biopsy at the age of
4.5 years. He was identified as having cervical A. naeslundii
infection. The patient presented with a tender, cervical fistu-
lizing abscess while receiving cotrimoxazole and itraconazole
prophylaxis. Culture from the biopsy yielded A. naeslundii. He
was treated orally with amoxicillin, azithromycin, and clinda-
mycin for 1 year and fully recovered.
Patient 3. Patient 3 was a 28-year-old Hispanic woman
born and raised in the United States with p22phox-deficient,
autosomal-recessive CGD. She had a history significant for
multiple staphylococcal liver abscesses and cervical A. naeslun-
dii lymphadenitis requiring adenectomy. She was admitted with
fever and a moderate cough. A CT showed multiple new lung,
liver, and tubo-ovarian abscesses. Fine-needle aspirations of
multiple abscesses yielded Actinomyces gerensceriae. She un-
derwent radiofrequency ablation of her liver abscesses and re-
ceived intravenous penicillin G (20 million U per day), which
caused her multiple abscesses to diminish. She received intra-
venous antibiotics for 3 months with steady improvement. She
continued to take oral azithromycin for the next 21 months
without recurrence.
Patient 4. Patient 4 was a 19-year-old white woman from
the United States with highly lyonized X-linked CGD and cu-
taneous lupus. She developed hoarseness and tender, enlarging
bilateral cervical lymphadenopathy. The cervical lymphadenop-
athy was from an infected, necrotizing, cervical lymph node. After
minimal response to combined treatment with levofloxacin, van-
comycin, and itraconazole, bilateral cervical lymphadenectomy
yielded actinomycosis (not further speciated). The patient’s reg-
imen was changed to vancomycin, imipenem, and clindamycin.
After the patient developed leukopenia 2 weeks into therapy, her
antibiotics were changed from imipenem to intravenous peni-
cillin G (4 million U every 4 h), which she tolerated well. The
patient was discharged home with a prescription for oral clin-
damycin and intravenous penicillin and her condition resolved.
Patient 5. Patient 5 was a 13-year-old African American
boy with X-linked CGD diagnosed at 6 weeks of age. He had
persistent colitis and recurrent fungal pulmonary infections,
requiring multiple pulmonary resections. He developed new
cervical lymphadenopathy while he had right lower-lobe pneu-
monia. The cervical adenopathy had CT attenuation charac-
teristics consistent with necrosis. Lymphadenectomy cultures
yielded Burkholderia gladioli, Streptococcus mitis, and Actino-
myces species. Dental evaluation found a right upper tooth with
significant decay, which was removed. He was subsequently
stable and continued to take meropenem for 3 weeks until
discharge. The patient’s cervical lymphadenopathy was resolved
1 month later.
Patient 6. Patient 6 was a 7-year-old boy of French-Al-
gerian origin with X-linked CGD. He was diagnosed as having
a hepatic abscess (Figure 1A) and a retrocardiac infiltration of
the left lung. The results of ultrasonography-guided liver punc-
ture were positive for A. naeslundii by culture and 16S ribo-
somal DNA (rDNA) sequencing with typical histologic findings
(Figure 1B). Despite intravenous amoxicillin, amikacin, and
ciprofloxacin guided by in vitro susceptibility, hepatic lesions
and fever persisted. Treatment was changed to intravenous cip-
rofloxacin, imipenem, and vancomycin for 70 days, leading to
partial improvement. For a persistent hepatic mass, he received
repeated granulocyte transfusions and surgical removal of the
abscess. He gradually recovered while taking oral amoxicillin
and clarithromycin for 6 months. At the age of 8 years, he was
admitted to the hospital with vomiting, epigastric pain, and
weight loss. Abdominal ultrasonography and CT showed typical
signs of actinomycosis (Figure 1A), but culture from a biopsy
of the gastric wall and 16S rDNA polymerase chain reaction
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Figure 1. A, Radiologic signs of abdominal actinomycosis on a computed tomographic (CT) scan (patient 6). Abdominal ultrasonography revealedsegmentary
portal hypertension and perigastric and esophageal varices (not shown); CT scan showed splenomegaly and thrombosis of the splenic vein (extension
delimited by white stars), multiple mesenteric lymph nodes (black arrow), gastric wall thickening (white arrow), and a peripancreatic mass (white arrowhead).
B, Histologic analysis of abdominal actinomycosis (patient 6). Liver histologic analysis after liver puncture in patient 6 showed extensive parenchymal
necrosis and multiple abscesses with filamentous gram-positive bacteria within the granule surrounded by neutrophil “clubbing” cells typical for actinomycosis
(original magnification, 10 and 100; Gram stain on the left and Grocott stain on the right).
(PCR) results were negative. Treatment with corticosteroids (1
mg/kg daily), intravenous clindamycin (45 mg/kg daily), and
penicillin G (470,000 IU/kg daily) for 15 days, followed by oral
clindamycin and amoxicillin, led to clinical improvement. Eight
months later, the disease recurred and gradually improved with
treatment with intravenous amoxicillin and clindamycin for 33
days and monitored plasma levels of oral azithromycin. The
boy is now well while receiving oral prophylaxis with azith-
romycin, amoxicillin, and clindamycin.
Patient 7. Patient 7 was a 16-year-old Slovenian boy with
X-linked CGD who developed fever, chills, and increasing pain
in the right upper abdomen while under irregular treatment
with interferon-g. Ultrasonography revealed a solitary lesion in
the right liver lobe; a histologic specimen taken during surgery
showed intense neutrophil infiltration and congestion of the
adjacent sinusoids. Cefotaxime, cloxacillin, and metronidazole
for 2 weeks did not lead to resolution. Ultrasonography-guided
drainage of the abscess yielded Actinomyces meyeri. Treatment
with intravenous penicillin G was given for 2 months, leading
to complete regression of the lesion. The patient was then tran-
sitioned to oral penicillin V for 1 year, without evidence of
recurrence.
Patient 8. Patient 8 was a 38-year-old, white, American
man with X-linked CGD diagnosed at 6 years of age. He had
had multiple liver abscesses, pneumonias, and severe chronic
obstructive pulmonary disease. Multiple liver abscesses were
found to harbor A. naeslundii. Six months of amoxicillin ther-
apy led to resolution. However, when hepatic abscesses re-
curred, he was treated with multiple intravenous regimens (in-
cluding piperacillin-tazobactam, rifampicin, linezolid, penicil-
lin) with minimal benefit. Additional liver biopsy specimens
revealed only degenerating gram-positive debris. Radiofre-
quency ablation of the persistent abscesses was tolerated well.
Six months later he underwent radiofrequency ablation of a
different deep hepatic abscess, after which his lesions remained
stable for a year. During that time his oral regimen consisted
primarily of double-strength trimethoprim-sulfamethoxazole
twice per day and voriconazole. He has remained free of re-
currence for 3 years.
Patient 9. Patient 9 was a 10-year-old Saudi Arabian boy
with p22phox-deficient, autosomal-recessive CGD. He had had
severe recurrent lymphadenitis, pneumonia and septicemia, os-
teomyelitis, and meningitis with cerebral aneurysm and brain
infarction due to Aspergillus fumigatus. During evaluation for
hematopoietic stem cell transplantation, a CT scan showed ero-
sion of the fifth left posterior rib and pulmonary lesions sug-
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gestive of aspergillosis. Examination of an open-lung biopsy
specimen demonstrated granulomatous lesions with microab-
scesses and a polymorphic inflammatory infiltrate with clus-
tered histiocytes and multinucleated giant cells. No pathogen
was identified by staining, culture, or PCR of the abscess fluid.
Treatment with voriconazole and caspofungin was ineffective.
With the appearance of new inflammatory lesions in the left
upper lobe and cervical lymphadenitis, additional complement
fixation tests (CFTs) for A. naeslundii produced positive results
(titers for patients, 1:80–1:160; for controls, 1:20–1:40). 5-
Flucytosine, interferon-g, and granulocyte transfusions led to
slow resolution of the lesions. The patient underwent HLA-
genoidentical hematopoietic stem cell transplantation at the age
of 10 years and has remained healthy since.
Patient 10. Patient 10 was a 3-year-old Swiss boy with X-
linked CGD diagnosed at 8 months of age who had had re-
current cervical lymph node abscesses and pneumonias. He
was diagnosed as having A. naeslundii lymphadenitis by culture
from a lymph node biopsy. Actinomyces species had been iso-
lated before by culture from bronchoalveolar lavage fluid at the
age of 2 years, but both results were interpreted as contami-
nation. A. naeslundii was isolated again at the age of 7 years
by culture from a transthoracic biopsy specimen taken because
of persistent pneumonia. After 3 weeks treatment with intra-
venous clindamycin, minocycline, and ciprofloxacin, followed
by oral minocycline and ciprofloxacin, he stabilized, but an
open lung biopsy specimen at the age of 7 years showed per-
sistent infection. After 3 months of intravenous ceftriaxone and
teicoplanin, followed by 9 months of oral penicillin and tro-
vafloxacin, A. naeslundii has never been reisolated, neither by
culture from a mediastinal lymph node biopsy specimen taken
at the age of 8 years nor by culture from pleural effusion punc-
tures performed when the patient was 9 years old. Persisting
actinomycosis is supported by positive A. naeslundii CFT results
in serum from the ages of 4 years through 10 years (titers for
patient, 1:320–1:640; for controls, 1:20–1:40). Chest x-ray
films and high-resolution CT scans showed typical signs of
actinomycosis (Figure 2A); positron emission tomography con-
firmed active inflammation (Figure 2B). The patient died of
chronic renal insufficiency, likely due to prolonged treatment
with amphotericin B until the age of 6 years for suspected
chronic invasive A. fumigatus pneumonia, and cardiorespira-
tory failure at 15 years. No autopsy was performed.
METHODS
Culture of Actinomyces. Actinomyces grows best anaerobi-
cally, although many strains are microaerophilic. Specimens
were obtained, transported, and cultured anaerobically on sem-
iselective media. All strains were grown at 37C on sheep blood
agar plates with carbon dioxide added. Hematoxylin-eosin stain
was performed according to standard procedures.
16S rDNA PCR. 16S rDNA PCR was performed as pre-
viously described [12, 13].
Actinomyces serologic testing (CFTs). CFTs were per-
formed at University Hospital Zurich for patients 9 and 10.
The bacterial isolate was identified by conventional methods
[14]. A crude antigen of the A. naeslundii isolate from the
patient was prepared as described [15] and used to determine
the serologic response by complement fixation. A serum sample
from a patient with infection of a hip prosthesis by A. naeslundii
was used as a positive control [16]. Serum samples from the
virology routine laboratory were used as negative controls.
RESULTS
Clinical and therapeutic features of the patients are summarized
in Table 1. Survival was good overall, with 9 of the 10 patients
successfully treated for their infections. Although 3 of the 9
had apparent recurrences of infection, they were successfully
treated again. The 2 patients who underwent BMT had neither
flare nor progression of their Actinomyces infections. Therefore,
actinomycosis is largely survivable in CGD and controllable
during BMT. The patient who died had end-organ damage from
long-term use of amphotericin B, given to treat the radiographic
appearance of fungal infection.
All of our actinomycosis patients from the United States,
Europe, and the Middle East have defects in the cytochrome
B component of the NADPH oxidase. The X-linked form of
CGD accounts for ∼65%-70% of cases, whereas the p22phox-
deficient form accounts for less than 5% [1, 2]. The absence
of any cases of p47phox deficiency, the most common form of
autosomal-recessive CGD, suggests an important role for cy-
tochrome B function in Actinomyces infections.
Surgery was associated with successful treatment in this se-
ries, as suggested in previous series [17–19]. In several patients
(patients 3, 4, and 8), extensive medical management failed
before definitive surgery or infection ablation.
DISCUSSION
Actinomyces species belong to the oral commensal flora and
become pathogenic only under certain conditions. They col-
onize the human oral cavity in early childhood, and the prev-
alence rates of total Actinomycetes flora increase from 31% to
97% within the first 2 years of life [20]. Actinomyces species
reside in periodontal pockets, carious teeth, dental plaque, and
tonsillar crypts [21] and take advantage of infection, trauma,
or surgical injury to penetrate mucosal barriers [22]. Diagnosis
of actinomycosis is especially challenging in CGD because pa-
tients frequently do not have the typical symptoms and signs
of infection. In addition, most clinical signs of Actinomyces
infection are nonspecific. Actinomyces is fastidious, requiring
ideal growth conditions; only ∼50% of reported cases have
positive cultures [23]. Infection is frequently polymicrobial in
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Figure 2. Radiologic signs of pulmonary actinomycosis (patient 10). A, High-resolution computed tomographic (CT) scan showing (1) focal consolidation,
mediastinal and hilar lymph node enlargement, pleural effusion, and granulomatous lesions with partial calcification and (2) diffuse interstitial infiltration
from the age of 7 years on. B, Representative positron emission tomographic–CT scan confirming infectious foci with active inflammation (encircled).
otherwise healthy individuals, with Actinobacillus actinomyce-
temcomitans being the most common associated pathogen.
Other copathogens include Fusobacterium, Bacteroides, Hae-
mophilus, Eikenella, Staphylococcus, Streptococcus, Gemella, Neis-
seria, and Eubacterium species [24]. Definitive diagnosis rests
on isolating the organism from tissue or pus from a normally
sterile body site.
Most infections in immunocompetent individuals are cer-
vicofacial [18, 25]. Intrathoracic or abdominal disease is rare
[24, 26–31]. Cervicofacial infection may follow any injury to
the oral mucosa, even the simple eruption of a tooth [22], and
characteristically spreads by direct invasion of adjacent tissues.
Symptoms range from painless, slowly enlarging, fluctuant le-
sions (patients 1–3) to acute painful induration and widespread
infection. Nodular lesions complicated by draining sinus tracts
may extend through overlying skin or to adjacent bones or
tissues.
Hepatic disease has been reported in 15% of immunocom-
petent patients with abdominal actinomycosis, but only ∼7%
of primary hepatic actinomycosis cases are children [32, 33].
Hematogenous spread may occur through the portal vein from
a mucosal lesion or injury or from another abdominal focus
of infection [18]. In patients 3 and 6, fever and coughing as-
sociated with pulmonary infiltrates preceded the detection of
the hepatic abscess; pulmonary infiltrates suggest hematoge-
nous spread from these lesions. The most common presenting
manifestations of abdominal actinomycosis are fever, abdom-
inal pain, nausea, vomiting, and weight loss (patients 6–8).
Hepatic lesions may extend by direct contiguity to penetrate
the abdominal wall, the diaphragm, adjacent viscera, or retro-
peritoneal tissues [22]. Jaundice is rare, and liver function test
results may be variable. Intrahepatic masses may mimic neo-
plasm, liver abscesses, or miliary disease. Radiofrequency ab-
lation of the infected hepatic abscesses was performed in pa-
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Table 1. Patient Characteristics and Treatment of Actinomycosis
Patient
Age,
years Sex Genotype
Age at
diagnosis Site of actinomycosis Therapya Surgery Outcome
1 23 M gp91phox 7 years Cervical/submandibular lymph nodes Intravenous ceftriaxone-meropenem,
penicillin V, BMT
Yes Survived, no recurrence
2 6 M gp91phox 2 years Cervical lymph node Oral amoxicillin-azithromycin-
clindamycin
Yes Survived, no recurrence
3 28 F p22phox 6 months Cervical lymph node, lung/liver
abscess
Intravenous penicillin G, oral
azithromycin
RFA Survived, no recurrence
4 19 F gp91phox 12 years Cervical lymph nodes Intravenous vancomycin-imipenem-
clindamycin, oral clindamy-
cin–intravenous penicillin G
Yes Survived, no recurrence
5 13 M gp91phox 6 weeks Cervical lymph node Intravenous meropenem Yes Survived, no recurrence
6 10 M gp91phox 7 years Liver Granulocyte transfusions, oral amoxi-
cillin-clarithromycin, corticosteroids,
intravenous amoxicillin-clindamy-
cin, azithromycin
Yes Survived, recurrence
7 16 M gp91phox 1 year Liver Ultrasonography-guided drainage, in-
terferon-g, intravenous penicillin
G, penicillin V
Yes Survived, no recurrence
8 38 M gp91phox 6 years Liver Oral amoxicillin, intravenous tri-
methoprim-sulfamethoxazole, in-
travenous voriconazole
RFA Survived, recurrence
9 10 M p22phox 1 year Lung, cervical lymph node BMT, granulocyte transfusions, 5-flu-
cytosine, interferon gamma
No Survived, no recurrence
10 2 M gp91phox 8 months Lung, cervical lymph node Intravenous clindamycin-minocycline-
ciprofloxacin, oral minocycline-cipro-
floxacin, intravenous ceftriaxone-
teicoplanin, oral
penicillin-trovafloxacin
Yes Recurrence, died
NOTE. BMT, bone marrow transplantation; RFA, radiofrequency ablation.
a Items in boldface type indicate that the antibiotic therapy was apparently effective against infection with Actinomyces species.
tients 3 and 8 because of their high risk for further hepatic
surgery.
Pulmonary actinomycosis is extremely rare in childhood,
with only 47 cases reported in the past 25 years in the English-
language literature [24]. It usually occurs after inhalation or
aspiration of endogenous microorganisms of the oropharynx
in immunocompetent persons with poor oral hygiene or from
cervicofacial extension [34]. The usual presentation is a mass
in the mediastinum or lung, but it can also manifest as diffuse
or local pneumonia, pleural empyema, or an endobronchial
mass. Rib involvement is common, with Actinomyces species
being able to induce bone resorption [18]. Most individuals
present with cough, chest wall pain, weight loss, and fever
(patients 3 and 10). Less commonly patients may have he-
moptysis [35] or superior vena cava syndrome [18]. Draining
sinuses have been reported in up to 11% of cases [24] but were
absent in our patients. Pulmonary actinomycosis has no specific
clinical or radiologic findings and closely mimics tuberculosis,
lung abscess, tumor, fungal infections, and pulmonary infarc-
tions [36]. Patients with CGD may also have pulmonary gran-
ulomatous lesions or fungal infections, as suspected and em-
pirically treated in patient 10. The most common CT findings
include central necrosis, cavities, mediastinal or hilar lymphade-
nopathy, endobronchial calcified nodules, and pleural effusion,
all of which were present in patient 10. He also showed localized
bronchiectasis, irregular bronchial wall thickening, and irregular
peribronchial consolidation with abscess formation.
The gold standard for diagnosis of actinomycosis is isolation
and culture from a usually sterile body site. Molecular iden-
tification by 16S PCR gives another level of certainty and allows
definitive speciation [12, 13, 37, 38]. Unfortunately, in patient
9, only serologic testing revealed the presence of Actinomyces
species. Because Actinomyces species colonize skin and mucosa
even in healthy individuals, isolation from nonsterile body sites
is not sufficient for proof of infection. Therefore, detection of
Actinomyces species in bronchoalveolar lavage was confirmed
by open-lung biopsy in patient 10.
Two principles of actinomycosis treatment have evolved dur-
ing the past 50 years. The disease should be treated with high
doses of antimicrobials for a prolonged period [18, 39] because
of the avascularity and induration of infected areas. We use
intravenous treatment for 2–6 weeks followed by oral therapy
for at least 6–12 months. The antibiotic of choice is penicillin.
In cases of allergy or nonresponse, alternatives include eryth-
romycin, tetracycline, clindamycin, cephalosporins, merope-
nem, and chloramphenicol [18, 40]. Frequent coinfections with
other microbes make combination therapy advisable.
The susceptibility of patients with CGD to infection with
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catalase-negative Actinomyces species confirms that catalase
production is neither necessary nor sufficient for microbial
virulence in CGD [41–43]. The recent recognition of the central
role of superoxide in potassium flux into the phagolysosome
and potassium’s role in activating killing explain the lack of
importance of microbial hydrogen peroxide and, therefore, cat-
alase in the pathogenesis of infections in CGD [44]. Infections
in CGD are caused by a subset of catalase-producing pathogens,
which are thought to deprive the CGD phagocyte of the op-
portunity to use microbial-derived oxidative metabolites [1] by
scavenging their own hydrogen peroxide via the production of
catalase. However, most catalase-positive organisms do not
cause disease in CGD [44]. The addition of this previously
recognized uncommon human pathogen to the CGD infection
list will allow better characterization of infection susceptibility
in CGD. To prevent the chronic debilitating effects of inade-
quately treated infection and the unnecessary toxic effects of
improper anti-infectious treatment, a high level of vigilance for
Actinomyces infection is necessary in patients with CGD. The
clinical manifestations, sites, and outcome of infection with
Actinomyces species in other patients with CGD are important
subjects for future investigation.
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